Photo from wikipedia
Essentials Acquired thrombotic thrombocytopenic purpura (aTTP) is linked with significant morbidity/mortality. Caplacizumab's effect on major thromboembolic (TE) events, exacerbations and death was studied. Fewer caplacizumab‐treated patients had a major TE… Click to show full abstract
Essentials Acquired thrombotic thrombocytopenic purpura (aTTP) is linked with significant morbidity/mortality. Caplacizumab's effect on major thromboembolic (TE) events, exacerbations and death was studied. Fewer caplacizumab‐treated patients had a major TE event, an exacerbation, or died versus placebo. Caplacizumab has the potential to reduce the acute morbidity and mortality associated with aTTP.
Keywords:
thromboembolic events;
events exacerbations;
acquired thrombotic;
thrombotic thrombocytopenic;
major thromboembolic;
thrombocytopenic purpura
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!